KAN-101

DRUG2 trials

Sponsors

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

Conditions

Celiac DiseaseCoeliac Disease

Phase 1

Assessment of KAN-101 in Celiac Disease (ACeD)

CompletedNCT04248855

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SACeliac Disease

Start: 2020-01-21End: 2021-10-08Updated: 2024-08-06

Phase 2

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

CompletedNCT06001177

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SACeliac Disease, Coeliac Disease

Start: 2023-12-13End: 2025-01-13Updated: 2025-12-18

Related Papers

Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial.

2023-06-1437 citations